Helive is the first inactivated hepatitis A vaccine in China, developed by Beijing SINOVAC itself. It has independent intellectual property rights. “It is considered of high purity and good safety. Both its immune effect and quality have reached internationally advanced level of products of the same kind, which has made up the blank in China” identified by experts. It possesses the following features: rapid production of protective antibody, enabling its application in emergency inoculation for epidemic outbreak of hepatitis A; strong immunogenicity, so that two whole range inoculations can provide protection as long as 20 years; thorough inactivation of hepatitis A virus, without live virus; highly purified, with no antiseptics; slight side effect with low incidence rate; good stability. Healive is the most effective method to prevent hepatitis A. Meanwhile, it is also the first brand of hepatitis A vaccine in China at present.

Bilive is the first inactivated combined hepatitis A and B vaccine in China, developed by Beijing SINOVAC itself. It has independent intellectual property rights. The combination of inactivated hepatitis A vaccine and genetically engineered hepatitis B vaccine has the following advantages: decreasing frequency of inoculation, alleviating inoculation pain, and lowering cost. Compared with univalent inactivated hepatitis A vaccine and recombinant yeast hepatitis B vaccine, it has the same immune effect. It is suitable for intensive immunization.

Anflu is a split influenza vaccine developed by Beijing SINOVAC itself. It got new drug certificate issued by State Food and Drug Administration in February, 2005 and production number in July, 2005. Now it has been produced in large scale and put on the market. It is recommended for use in adults and children older than 6 months. It is especially recommended to populations that vulnerable to related complications, such as children, aged people, weaklings, and people in influenza prevalent areas.